National Comprehensive Cancer Network® (NCCN®) Recommendation
Avelumab maintenance is the ONLY NCCN CATEGORY 1 and PREFERRED
immunotherapy option for both cisplatin-eligible and -ineligible patients
with locally advanced or metastatic urothelial carcinoma (UC) that has
not progressed on first-line platinum-containing chemotherapy.3
Category 1=Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.
NCCN=National Comprehensive Cancer Network® (NCCN®)
Preferred intervention=Interventions that are based on superior efficacy, safety, and evidence; and, when appropriate, affordability.
